| Trial ID # | Retrospective Study: Metronomic Oral Cyclophosphamide (MOC) |
| Phase | II |
| Drug Class | Chemotherapy |
| Drug Name | Cyclophosphamide |
| Alternate Drug Names | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida |
| Drugs in Trial | Cyclophosphamide |
| Eligible Participant | Platinum resistant or refractory ovarian cancer |
| Patients Enrolled | 20 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, evaluated per RECIST |
| Efficacy | ORR: 15% (1CR, 2PR, n=20) |
| Conclusion | Metronomic oral cyclophosphamide may provide a valid alternative for the palliative treatment of heavily pretreated recurrent ovarian cancer |
| Reference | Ferrandina G et al. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study. BMC Cancer (2014) 14:947 |